Abstract
The two novel approaches recently introduced for the treatment of resistant hypertension, i.e. carotid baroreceptor stimulation and renal denervation, share a number of similarities but are also characterized by important differences. The similarities include the evidence that both interventions have as common pathophysiological background the state of sympathetic overdrive characterizing essential hypertension. In addition both procedures 1) are invasive, 2) exert in the short-term period clearcut blood pressure lowering effects and 3) still face a number of open questions, particularly related to the long-term blood pressure lowering effects, impact on end-organ damage and on cardiovascular events. The differences include the fact that two procedures act on distinct targets that trigger sympathetic activation and consequently blood pressure increase. In addition, only in the case of carotid baroreceptor stimulation the blood pressure effects can be easily assessed immediately following the implantation. Finally, the economic costs, metabolic effects and impact on vagal modulation of heart rate are different between the two interventions. This paper will provide a comparison of the background, effects and outcome of renal denervation and carotid baroreceptor stimulation, stressing whenever possible the clinical implications of the main features of the two interventions.
Keywords: Resistant hypertension, renal denervation, carotid baroreceptor stimulation, symapthetic activity, end organ damage.
Current Vascular Pharmacology
Title:Similarities and Differences Between Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation
Volume: 12 Issue: 1
Author(s): Guido Grassi, Gino Seravalle, Gianmaria Brambilla, Francesca Cesana, Cristina Giannattasio and Giuseppe Mancia
Affiliation:
Keywords: Resistant hypertension, renal denervation, carotid baroreceptor stimulation, symapthetic activity, end organ damage.
Abstract: The two novel approaches recently introduced for the treatment of resistant hypertension, i.e. carotid baroreceptor stimulation and renal denervation, share a number of similarities but are also characterized by important differences. The similarities include the evidence that both interventions have as common pathophysiological background the state of sympathetic overdrive characterizing essential hypertension. In addition both procedures 1) are invasive, 2) exert in the short-term period clearcut blood pressure lowering effects and 3) still face a number of open questions, particularly related to the long-term blood pressure lowering effects, impact on end-organ damage and on cardiovascular events. The differences include the fact that two procedures act on distinct targets that trigger sympathetic activation and consequently blood pressure increase. In addition, only in the case of carotid baroreceptor stimulation the blood pressure effects can be easily assessed immediately following the implantation. Finally, the economic costs, metabolic effects and impact on vagal modulation of heart rate are different between the two interventions. This paper will provide a comparison of the background, effects and outcome of renal denervation and carotid baroreceptor stimulation, stressing whenever possible the clinical implications of the main features of the two interventions.
Export Options
About this article
Cite this article as:
Grassi Guido, Seravalle Gino, Brambilla Gianmaria, Cesana Francesca, Giannattasio Cristina and Mancia Giuseppe, Similarities and Differences Between Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation, Current Vascular Pharmacology 2014; 12 (1) . https://dx.doi.org/10.2174/15701611113119990142
DOI https://dx.doi.org/10.2174/15701611113119990142 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Non-peptide Antagonists and Agonists of the Bradykinin B2 Receptor
Current Medicinal Chemistry Cardiovascular Risk in Perimenopausal Women
Current Vascular Pharmacology Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease
Current Vascular Pharmacology PET Molecular Imaging of Hypoxia in Ischemic Stroke: An Update
Current Vascular Pharmacology Bioorganic Compounds Produced by the Fungus Monascus and their Use in Health Sciences and Medicine
Mini-Reviews in Organic Chemistry Comparison of Pharmacodynamics and Celiac Effects of Olmesartan Medoxomil Formulations by using Olmesartan-induced Celiac-rat-model
Current Drug Delivery Why Not All Hypertensive Patients Are Tachycardic at Rest?
Current Pharmaceutical Design Molecular Determinants of the Cardiometabolic Phenotype
Endocrine, Metabolic & Immune Disorders - Drug Targets Endothelins and the Role of Endothelin Antagonists in the Management of Posttraumatic Vasospasm
Current Pharmaceutical Design Zwitterionic Imidazolium Salt: An Efficient Organocatalyst for the One-Pot Synthesis of 5,6-Unsubstituted 1,4-Dihydropyridine Scaffolds
Current Organocatalysis Graphical Abstracts:
Current Hypertension Reviews Editorial (Thematic Issue: G-protein Coupled Receptors in Vascular Biology: Implication in Health and Disease)
Current Vascular Pharmacology Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace
Adolescent Psychiatry Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva.
Current Molecular Medicine Biopsychosocial Predictors of Cognitive Impairment in the Elderly: A Case-control Study
Current Psychiatry Research and Reviews Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis
Current Neurovascular Research Syncytin and GCMa: Key Regulators in Human Placental Physiology and in Pre-Eclampsia
Current Women`s Health Reviews Central Nervous System Manifestations in Systemic Lupus Erythematosus
Current Rheumatology Reviews Pharmacogenomics and Sepsis-Induced Renal Failure: Effects of β 2-Adrenoceptor Function on the Course of Sepsis
Current Pharmacogenomics and Personalized Medicine Cyclic Nucleotide and Protein Kinase Signaling in Hypertensive Pulmonary Arterial Smooth Muscle
Current Respiratory Medicine Reviews